BioAdaptives Launches XcellaraHeart(TM) for Cardiovascular Wellness

BioAdaptives (OTC: BDPT) has announced the upcoming commercial launch of XcellaraHeart(TM), a cardiovascular wellness supplement that combines its clinically proven Xcellara(TM) stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The company states that the Xcellara(TM) base is supported by a randomized, double-blind, placebo-controlled clinical trial demonstrating an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, while Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway associated with cellular trafficking and cardiovascular repair biology. XcellaraHeart(TM) is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August. BioAdaptives describes the product as part of a two-part cardiovascular wellness strategy combining stem/progenitor cell mobilization with cardiovascular signaling support, and a scientific evidence dossier detailing the formulation is available on the company’s product website. The company is the developer of the Xcellara(TM) line of stem cell mobilization and tissue-homing supplements, with the flagship Xcellara(TM) base formula being the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com. The complete scientific evidence dossier for the XcellaraHeart(TM) formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara(TM) base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two. NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, distributed this press release. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, delivering a wide range of services including access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.